Immunosuppression and cardiovascular dysfunction in patients with severe versus mild coronavirus disease 2019: a case series.
COVID‐19
SARS‐CoV‐2
cardiovascular dysfunction
immunology
immunosuppression
immunotherapy
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
04
2020
revised:
09
09
2020
accepted:
09
09
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
8
10
2020
Statut:
epublish
Résumé
As coronavirus disease 2019 (COVID-19) continues to spread globally, we aimed to describe and compare changes in the immune and cardiovascular systems of patients with mild versus severe COVID-19 at different time points during the course of disease. One hundred and one patients diagnosed with COVID-19 who underwent serial peripheral blood collection and chest computed tomography (CT) imaging were enrolled in this study and grouped by the severity of their illness. Changes in the immune and cardiovascular systems were analysed and compared between groups. The study included 43 women and 58 men, with a median age of 45 years (interquartile range [IQR], 16-71). We identified spleen shrinkage in 27.7% of study patients. Ratios of spleen volume to patient (skin) volume were compared, with evidence that severe patients had more splenic shrinkage than mild patients. Lymphopenia was observed in 65.3% of patients, and 27.3% of patients had persistently low levels of lymphocytes after discharge. Tachycardia occurred mainly during the first 2 days of hospitalisation, with increases in creatine kinase-myocardial band levels in 10 (9.9%) patients and arrhythmias in 16 (15.8%) patients. In addition to pulmonary manifestations, our study demonstrated that other organ systems can also be affected during COVID-19 infection, with evidence of immunosuppression and cardiovascular dysfunction, which may contribute to increased mortality rates in critically ill COVID-19 patients.
Identifiants
pubmed: 33024561
doi: 10.1002/cti2.1188
pii: CTI21188
pmc: PMC7527927
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1188Informations de copyright
© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):3799-804
pubmed: 24572573
Transpl Int. 2020 Jul;33(7):824-825
pubmed: 32236983
Eur J Immunol. 2017 Sep;47(9):1414-1426
pubmed: 28744851
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Microbiol. 2019 May 10;10:1057
pubmed: 31134045
J Virol. 2006 Jun;80(12):5927-40
pubmed: 16731931
Lancet. 2020 Apr 4;395(10230):1111
pubmed: 32220278
Expert Rev Clin Immunol. 2020 May;16(5):465-470
pubmed: 32237901
Clin Transl Immunology. 2019 Aug 05;8(8):e1073
pubmed: 31406574
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Clin Transl Immunology. 2019 Jul 08;8(7):e1067
pubmed: 31312450
Transpl Int. 2009 Nov;22(11):1041-50
pubmed: 19624493
Ther Clin Risk Manag. 2018 Apr 11;14:653-657
pubmed: 29695909
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Clin Sci (Lond). 2020 Mar 13;134(5):543-545
pubmed: 32167153
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Curr Opin Virol. 2012 Jun;2(3):264-75
pubmed: 22572391
J Clin Med. 2020 Feb 11;9(2):
pubmed: 32054124
Br J Haematol. 2020 May;189(3):428-437
pubmed: 32297671
Emerg Microbes Infect. 2020 Dec;9(1):558-570
pubmed: 32172672
Lancet. 2020 May 2;395(10234):1407-1409
pubmed: 32278362
Clin Transl Immunology. 2020 Feb 19;9(2):e1115
pubmed: 32099652
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
Int J Mol Sci. 2020 Mar 25;21(7):
pubmed: 32218340
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Eur Radiol. 2020 Jun;30(6):3486-3496
pubmed: 32055946
Mediators Inflamm. 2010;2010:781235
pubmed: 20981241
HPB (Oxford). 2020 Feb 17;:
pubmed: 32081539
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Clin Transl Immunology. 2019 Nov 05;8(11):e01087
pubmed: 31709051